display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - L1 - BRAF wild
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cometinib IMspire-170
nivolumab based treatment
nivolumab alone CheckMate 066
Immune checkpoint association
nivolumab plus ipilimumab CheckMate 069 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons